ERBB2 and breast cancer: The PI3K pathway is altered in up to 50% of HER2-enriched BC, mainly as a consequence of PIK3CA mutations or PTEN loss (Nagata et al., 2004; Isakoff et al., 2005; Wisinski et al., 2016).